Alphabet's Calico Life Sciences has secured exclusive global rights, barring greater China, to Mabwell Bioscience's IL-11 targeted monoclonal antibody 9MW3811, an investigational asset intended for age-related diseases. The deal includes up to $571 million in payments, with $25 million upfront. Mabwell’s phase 1 trials in China and Australia, alongside an FDA investigational new drug application, showcase the antibody’s potential in idiopathic pulmonary fibrosis. Calico's acquisition aligns with its mission to explore aging biology, complementing existing partnerships with AbbVie and MIT's Broad Institute.